{
    "clinical_study": {
        "@rank": "35223", 
        "arm_group": [
            {
                "arm_group_label": "Ademetionine 1", 
                "arm_group_type": "Experimental", 
                "description": "Ademetionine 2000mg"
            }, 
            {
                "arm_group_label": "Ademetionine 2", 
                "arm_group_type": "Experimental", 
                "description": "Ademetionine 1000mg"
            }, 
            {
                "arm_group_label": "Ademetionine 3", 
                "arm_group_type": "Active Comparator", 
                "description": "no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an evaluation of adenosine methionine for treatment of chronic hepatitis b patients\n      with cholestasis efficacy and safety of multicenter, randomized, open label clinical trial."
        }, 
        "brief_title": "Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis B", 
            "Cholestasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cholestasis", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "evaluation of adenosine methionine for treatment of chronic hepatitis b patients with\n      cholestasis efficacy and safety"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. from 18-65 years old\n\n          2. diagnosed as hepatitis B, previous has HBV or HBsAg(+)>6 months, and now HBsAg or HBV\n             DNA(+)\n\n          3. with intrahepatic cholestasis: meet EASL 2009 diagnoses criteria ALP>1.5ULN and\n             GGT>3ULN or STB>2ULN\n\n        Exclusion Criteria:\n\n          1. liver mass, liver carcinoma\n\n          2. liver failure\n\n          3. non-hepatic diseases caused jaundice\n\n          4. obstructive jaundice"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998620", 
            "org_study_id": "XMX-HBV-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ademetionine 2", 
                "description": "Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg  po bid with general antiviral treatment for 8 weeks", 
                "intervention_name": "Ademetionine   2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ademetionine 1", 
                "description": "Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks", 
                "intervention_name": "Ademetionine 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ademetionine 3", 
                "description": "no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks", 
                "intervention_name": "Ademetionine 3", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis B", 
            "Cholestasis"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "chenlian@shaphl.org", 
                "last_name": "Liang Chen, Doctor", 
                "phone": "00862137990333"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200000"
                }, 
                "name": "Public Health Clinical Center Affiliated to Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis", 
        "overall_contact": {
            "email": "chenlian@shaphl.org", 
            "last_name": "Liang Chen", 
            "phone": "00862137990333"
        }, 
        "overall_official": {
            "affiliation": "Public Health Clinical Center Affiliated to Fudan University", 
            "last_name": "Liang Chen", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "levels of serum total bilirubin declined from baseline", 
                "measure": "levels of serum total bilirubin declined from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Alkaline Phosphatase", 
                "measure": "Alkaline Phosphatase", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }, 
            {
                "description": "Gamma-Glutamyl Transpeptidase", 
                "measure": "Gamma-Glutamyl Transpeptidase", 
                "safety_issue": "Yes", 
                "time_frame": "10 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "level of serum direct bilirubin decline from baseline", 
                "measure": "level of serum direct bilirubin decline from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 6 weeks, 10 weeks"
            }, 
            {
                "description": "level of serum bile acids decline from baseline", 
                "measure": "level of serum bile acids decline from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 6 weeks, 10 weeks"
            }, 
            {
                "description": "glutamic pyruvic transaminase", 
                "measure": "glutamic pyruvic transaminase", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 6 weeks, 10 weeks"
            }, 
            {
                "description": "glutamic oxaloacetic transaminase", 
                "measure": "glutamic oxaloacetic transaminase", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 6 weeks, 10 weeks"
            }
        ], 
        "source": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}